AEV 400
Alternative Names: AEV-400Latest Information Update: 08 Feb 2023
At a glance
- Originator AevisBio
- Developer AevisBio; Korea Research Institute of Chemical Technology
- Class Antineoplastics
- Mechanism of Action Proteolysis
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 04 Jan 2023 Early research in Solid tumours in South Korea, prior to January 2023 (AevisBio pipeline, January 2023)
- 09 Mar 2022 AevisBio and Korea Research Institute of Chemical Technology enters a R&D agreement to develop anti-cancer therapies (AevisBio pipeline, March 2022)